Nutriband Inc. Secures U.S. Patent for AVERSA(TM) Technology, Aiming to Curb Drug Abuse

Nutriband Inc. (NASDAQ: NTRB) has recently been granted a U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, a development that significantly expands the company's intellectual property coverage in the domestic market. This technology is specifically designed to mitigate the risks associated with the misuse, abuse, and accidental exposure of transdermal drugs that have a high potential for abuse, such as fentanyl.

The opioid crisis continues to be a major public health emergency in the United States, with over 100,000 Americans dying annually from drug overdoses, many of which are linked to synthetic opioids like fentanyl. Nutriband's AVERSA(TM) technology represents a proactive approach to enhancing drug safety by integrating abuse-deterrent features directly into the drug delivery system. This innovation could play a pivotal role in addressing the dual challenges of ensuring patient access to necessary medications while preventing their misuse.

For more information on Nutriband Inc. and its developments, visit https://ibn.fm/NTRB.